|Kai Fu, M.D., Ph.D.|
The findings are published in the November issue of the Journal of Clinical Oncology, the medical journal of the American Society for Clinical Oncology.
“These results are significant in that it gives oncologists a better understanding of the best way to personalize medical treatment for these patients and offer them hope for more positive outcomes,” said Kai Fu, M.D., associate professor in the department of pathology and microbiology.
STAT3, or signal transducer and activator of the transcription 3 gene, is part of a family known as the STAT genes that provide instructions for making proteins that are part of essential signaling pathways related to cell proliferation and survival within cells.
When these genes are activated, they move into the nucleus of the cell and bind to specific areas of DNA in regulatory regions near genes. The STAT proteins then regulate whether these genes are turned on or off.
Patients with this type of lymphoma are treated with a combination of immunotherapy using rituximab with a chemotherapy regimen that includes cyclophosphamide, doxorubicin, vincristine and prednisone, commonly referred to as R-CHOP.
“Using this combination of drug therapy usually has very good results but not in those patients with this specific type of lymphoma,” Dr. Fu said. “We wanted to find out why so we could figure out a way to change those outcomes.”
Dr. Fu and his team, along with UNMC investigators Julie Vose, M.D., James Armitage, M.D., John Chan, M.D., Dennis Weisenburger, M.D., and Timothy Greiner, M.D., initiated the study in 2005 with collaborators from 11 institutions around the world.
They began looking at the gene and found patients with high levels of the gene responded poorly to standard chemotherapy compared to those with lower levels.
The next step in the research is to use a specific STAT3 inhibitor to see if it helps the R-CHOP chemotherapy regimen work more efficiently and improve patient survival rates by identifying patients who are at higher risk, he said.
“We are very fortunate to be given the opportunity to be involved with many early phase clinical trials for the treatment of lymphoma including a new STAT3 inhibitor, which is based on this research,” Dr. Vose said.